Results 221 to 230 of about 41,551 (306)

Cannabidiol Protects Against 1‐Methyl‐4‐Phenylpyridinium and Manganese‐Induced Neurotoxicity via Nod‐Like Receptor Protein 3 Inflammasome Suppression

Journal of Biochemical and Molecular Toxicology, Volume 40, Issue 6, June 2026.
CBD oil exhibits neuroprotective effects in Parkinson's disease models by inhibiting NLRP3 inflammasome activation. It preserves dopamine levels and reduces α‐synuclein accumulation, suggesting its potential as a therapeutic strategy against neuroinflammation and neurodegeneration.
Göksun Demirel, Anıl Yirün, Deniz Arca Çakir, Hüseyin Özkan, Berfu Şura Güneş, Selen Selvi, Yeter EROL. Öztürk, Pınar Erkekoğlu   +7 more
wiley   +1 more source

Characterization of binding kinetics and intracellular signaling of new psychoactive substances targeting cannabinoid receptor using transition-based reweighting method. [PDF]

Elife
Dutta S, Shukla D.
europepmc   +1 more source

Advancing Canning Quality in Common Beans: An Integrated Farm‐to‐Can Framework Combining Breeding, Processing, and Artificial Intelligence

Legume Science, Volume 8, Issue 2, June 2026.
ABSTRACT Common beans (Phaseolus vulgaris L.) are essential raw material for the canning industry. This article reviews recent advances in assessing canning quality and the integration of artificial intelligence (AI) into breeding methodologies aimed at developing genotypes with superior yield and canning‐quality traits.
Arash Ghaitaranpour, Biniam Kebede, Mohsen Yoosefzadeh‐Najafabadi   +2 more
wiley   +1 more source

Opposing Synovial Cannabinoid Receptor Type 2 and Transient Receptor Potential Vanilloid 1 Expression in Painful Osteoarthritis. [PDF]

Cureus
Toups CA, Guillot LG, Redondo K, Jensen S, Klein J, Marrero L.   +5 more
europepmc   +1 more source

Diabetic Peripheral Neuropathy: Molecular Staging, Risk Factors, Therapeutics, and Emerging Trends

Med Research, Volume 2, Issue 2, Page 309-342, June 2026.
The heterogeneous landscape of DPN can be unified through a tripartite pathogenic model encompassing progressive stages of metabolic dysregulation, chronic inflammation, and overt neuronal damage. Within this framework, six clinical subtypes were identified, namely, hyperglycemia‐driven, dyslipidemia‐driven, inflammation‐driven, dysvascularity‐driven ...
Xiaofeng Dai, Mingze Tang
wiley   +1 more source

Altered NPK Fertigation With Triacontanol Supplementation Indicates Promising Improvements to Cannabis Flower Yield and Volatile Composition

New Zealand Journal of Crop and Horticultural Science, Volume 54, Issue 2, June 2026.
Cannabis is cultivated for its flowers, which are abundant in volatile terpenes that impact sensory and therapeutic properties. These compounds are therefore targets for enhancement during cultivation. One such strategy is the provision of biostimulants, such as the long‐chain primary alcohol triacontanol (TRIA), which may be sourced from plant waxes ...
Kimber Wise, Tomer Simovich, Jamie Selby‐Pham   +2 more
wiley   +1 more source

Waxy- or Putty-Like Materials as a Novel Drug Preparation for Synthetic Cannabinoid Receptor Agonists: Detection in Prisons and In Vitro Cannabinoid Receptor Activity. [PDF]

Drug Test Anal
Timmerman A, Deventer MH, Andrews R, Reid R, Marland V, Edwards D, Pudney CR, Nic Daéid N, Stove CP, Norman C.   +9 more
europepmc   +1 more source

A Feasibility Assessment of the FDA Adverse Event Reporting System for the Detection of Cannabis‐Related Safety Signals

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 6, June 2026.
ABSTRACT Background The applicability of spontaneous reporting systems such as the US Food and Drug Administration Adverse Event Reporting System (FAERS) to detect cannabis‐related safety signals remains unclear due to the potential for discrepant reporting patterns between pharmaceutical and non‐pharmaceutical cannabis‐derived products (CDPs ...
Priscilla O. M. V. Lopes, Cory S. Harris, Christopher A. Gravel   +2 more
wiley   +1 more source

Development of Carborane-Based Benzothiazole Analogues as Cannabinoid Receptor Type 2 (CB₂R) Ligands. [PDF]

ACS Omega
Ueberham L, Kazimir A, Deuther-Conrad W, Hey-Hawkins E.   +3 more
europepmc   +1 more source

How THC works: Explaining ligand affinity for, and partial agonism of, cannabinoid receptor 1. [PDF]

iScience
Shahbazi-Raz F, Meister D, Mohammadzadeh A, Trant JF.   +3 more
europepmc   +1 more source